Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20416635 | 0.82 | MEN1 (0.37) | MEN1OPRM1OPRD1KMT2AMAPK1 | |
| SCHEMBL20416582 | 0.81 | MEN1 (0.49) | MEN1OPRM1OPRD1KMT2AMAPK1 | |
| SCHEMBL20416631 | 0.80 | MEN1 (0.36) | MEN1OPRM1OPRD1KMT2AMAPK1 | |
| SCHEMBL20436545 | 0.79 | HSD11B1 (0.40) | HSD11B1CCNKDDB1CDK12GRM5 | |
| SCHEMBL14479643 | 0.77 | NR3C2 (0.41) | MEN1KMT2ANR3C2HSD11B1CCNK | |
| SCHEMBL21742200 | 0.76 | NR3C2 (0.46) | MEN1KMT2ANR3C2HSD11B1CCNK | |
| SCHEMBL3925148 | 0.75 | ADORA1 (0.44) | NR3C2HSD11B1CCNKDDB1CDK12 | |
| SCHEMBL30396325 | 0.75 | CCR2 (0.42) | MEN1KMT2ANR3C2SCN9AGRM5 | |
| SCHEMBL465792 | 0.75 | CCR2 (0.42) | MEN1KMT2ANR3C2SCN9AGRM5 | |
| SCHEMBL20416905 | 0.74 | PTGER2 (0.39) | MEN1KMT2ANR3C2HSD11B1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3570844-B1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | MEN1 3139/4885OPRM1 4284/4885OPRD1 4227/4885 |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | MEN1 3139/4885OPRM1 4284/4885OPRD1 4227/4885 |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | MEN1 3139/4885OPRM1 4284/4885OPRD1 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.